ISCO Stock Performance, Insider Transaction and News

ISCO - INTERNATIONAL STEM CELL CORPORA

Market Cap	808.44K	P/E	-	EPS this Y	-	Ern Qtrly Grth	-
Income	-131k	Forward P/E	-0.11	EPS next Y	-	50D Avg Chg	-28.00%
Sales	7.79M	PEG	-	EPS past 5Y	-	200D Avg Chg	-47.00%
Dividend	N/A	Price/Book	N/A	EPS next 5Y	-	52W High Chg	-78.00%
Recommedations	-	Quick Ratio	0.45	Shares Outstanding	8M	52W Low Chg	68.00%
Insider Own	53.77%	ROA	-7.87%	Shares Float	3.70M	Beta	0.50
Inst Own	-	ROE	-	Shares Shorted/Prior	-/-	Price	0.10
Gross Margin	59.16%	Profit Margin	-1.68%	Avg. Volume	1,864	Target Price	-
Oper. Margin	-22.45%	Earnings Date	Mar 28	Volume	4,358	Change	-31.27%

Healthcare | Biotechnology | United States

About INTERNATIONAL STEM CELL CORPORA

International Stem Cell Corporation, a clinical stage biotechnology company, focuses on the development of therapeutic and biomedical products in the United States, Asia, Europe, and internationally. It develops ISC-hpNSC, a neural stem cell program that has completed the Phase I clinical trial for the treatment of Parkinson's disease, as well as for treating stroke, traumatic brain injury, and Alzheimer's disease. The company also offers anti-aging skin care products, including ProPlus Advanced Defense Complex, ProPlus Advanced Recovery Complex, ProPlus Eye Firming Complex, ProPlus Neck Firming Complex, ProPlus Advanced Aqueous Treatment, ProPlus Collagen Booster, ProPlus Elastin Booster, and ProPlus Brightening Toner. In addition, it provides human cell culture products comprising human skin cells and reagents for the study of skin disease, toxicology, or wound healing; human cells from the heart and blood vessels, and reagents to study cardiovascular disease and cancer; human bronchial and tracheal cell lines for the study of toxicity, cystic fibrosis, asthma, and pathogenesis; and human mammary epithelial cell lines for the study of breast cancer, three dimensional culture, and carcinogen screening. Its human cell culture products also consists of adult stem cells and reagents for regenerative medicine; human prostate cells and specialized medium to study prostate disease; human renal and bladder cells and media to study renal and bladder diseases; human corneal cells and media for the study of corneal disease; human female reproductive system cells for the study of cellular physiology; human skeletal muscle cells for the study of biology, diabetes, insulin receptor studies, muscle metabolism, muscle tissue repair, and myotube development; and other cell culture reagents and supplements for the growth, staining, and freezing of human cells. International Stem Cell Corporation was founded in 2001 and is headquartered in San Diego, California.

ISCO Chatroom

Fullratio Posted - 04/09/24

$ISCO P/S is 89% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 03/27/24

$ISCO EV/Sales is 47% below its last 4 quarters average of 1.2: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 03/14/24

$ISCO P/S is 89% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 2 months ago

$ISCO EV/Sales is 43% below its last 4 quarters average of 1.2: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 02/22/24

$ISCO P/S is 83% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 02/12/24

$ISCO EV/Sales is 44% below its last 4 quarters average of 1.2: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 3 months ago

$ISCO P/S is 81% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 01/22/24

$ISCO EV/Sales is 43% below its last 4 quarters average of 1.2: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 01/14/24

$ISCO P/S is 86% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 12/23/23

$ISCO EV/Sales is 47% below its last 4 quarters average of 1.2: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 12/13/23

$ISCO P/S is 86% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Last10K Posted - 11/13/23

$ISCO just filed a 10-Q Quarterly Report with 5 financial statements and 50 disclosures: https://last10k.com/sec-filings/isco/0000950170-23-062890.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=isco

cctranscripts Posted - 11/13/23

International Stem Cell Just Filed Its Quarterly Report: Net Income (Loss) Pe... https://www.conferencecalltranscripts.org/summary/?id=12701294 $ISCO

risenhoover Posted - 11/13/23

$ISCO / International Stem Cell files form 10-Q https://fintel.io/doc/sec-international-stem-cell-corp-1355790-10q-2023-november-13-19674-6552?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

cctranscripts Posted - 5 months ago

Major owner of International Stem Cell was just granted 500,000 options https://www.conferencecalltranscripts.org/summary/?id=12687735 $ISCO

cctranscripts Posted - 5 months ago

Major owner of International Stem Cell was just granted 2,000,000 options https://www.conferencecalltranscripts.org/summary/?id=12687728 $ISCO

cctranscripts Posted - 09/27/23

Other definitive information statements https://www.conferencecalltranscripts.org/summary/?id=12571170 $ISCO

Last10K Posted - 09/18/23

$ISCO just filed with the SEC a New Agreement, a New Financial Obligation and a Financial Exhibit https://last10k.com/sec-filings/ISCO/0001683168-23-006510.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=ISCO

cctranscripts Posted - 09/18/23

Entry into a Material Definitive https://www.conferencecalltranscripts.org/summary/?id=12545972 $ISCO

Last10K Posted - 08/11/23

$ISCO just filed a 10-Q Quarterly Report with 5 financial statements and 48 disclosures. Access them all or just read their earnings: https://last10k.com/sec-filings/isco/0000950170-23-041762.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=10KQ2040F&utm_term=isco

cctranscripts Posted - 08/11/23

International Stem Cell Just Filed Its Quarterly Report: Net Income (Loss) Pe... https://www.conferencecalltranscripts.org/summary/?id=12447981 $ISCO

Fullratio Posted - 9 months ago

$ISCO P/S is 87% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 07/09/23

$ISCO EV/Sales is 41% below its last 4 quarters average of 1.2: https://fullratio.com/stocks/otc-isco/international-stem-cell

Fullratio Posted - 06/30/23

$ISCO P/S is 83% below its last 4 quarters average of 0.7: https://fullratio.com/stocks/otc-isco/international-stem-cell

EarningsInsider Posted - 06/21/23

International Stem Cell Co. Files SEC Form 8-K $ISCO https://www.marketbeat.com/stocks/OTCMKTS/ISCO/sec-filings/

cctranscripts Posted - 06/21/23

Submission of Matters to a Vote of Security https://www.conferencecalltranscripts.org/summary/?id=12300641 $ISCO

Last10K Posted - 06/21/23

$ISCO just filed with the SEC a Vote of Security Holders https://last10k.com/sec-filings/isco/0001683168-23-004312.htm?utm_source=stocktwits&utm_medium=forum&utm_campaign=8K&utm_term=isco

risenhoover Posted - 06/21/23

$ISCO / International Stem Cell files form 8-K - SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): June 14, 2023 INTERNATIONAL STEM CELL CORPORATI https://fintel.io/sf/us/isco?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

dividendinvestorbyeagle Posted - 06/21/23

$ISCO close increased > 10% (International Stem Cell Corp) https://www.dividendinvestor.com/dividend-news/?symbol=isco

cctranscripts Posted - 06/16/23

International Stem Cell director was just granted 475,205 options https://www.conferencecalltranscripts.org/summary/?id=12292567 $ISCO